Krensavage Asset Management LLC Boosts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Krensavage Asset Management LLC boosted its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 50.0% in the second quarter, Holdings Channel reports. The fund owned 6,000 shares of the biopharmaceutical company’s stock after purchasing an additional 2,000 shares during the period. Regeneron Pharmaceuticals accounts for about 1.4% of Krensavage Asset Management LLC’s portfolio, making the stock its 14th biggest position. Krensavage Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $3,741,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. SHP Wealth Management purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $26,000. Western Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals in the 1st quarter valued at $26,000. Titan Wealth CI Ltd purchased a new position in Regeneron Pharmaceuticals in the 4th quarter valued at $29,000. Mowery & Schoenfeld Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $29,000. Finally, Trust Co. of Vermont acquired a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at $29,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on REGN. JPMorgan Chase & Co. reduced their target price on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Cantor Fitzgerald boosted their price target on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Wells Fargo & Company increased their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating for the company in a research report on Monday, May 18th. Finally, Sanford C. Bernstein raised Regeneron Pharmaceuticals to a “hold” rating in a report on Wednesday, July 29th. Fourteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $800.36.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total value of $130,030.00. Following the sale, the director owned 17,303 shares of the company’s stock, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the transaction, the executive vice president owned 13,134 shares of the company’s stock, valued at approximately $11,163,900. This represents a 8.47% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 4,146 shares of company stock valued at $3,432,488. Company insiders own 6.97% of the company’s stock.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron’s presentation at the Wells Fargo Healthcare Conference may provide investors with additional detail on its pipeline, commercial portfolio and strategy. However, the available report is a transcript and does not identify a new market-moving announcement. Wells Fargo conference transcript
• Neutral Sentiment: Recent fund commentary is mixed: Harbor Funds discussed the stock’s bullish potential, while American Century Investments reported selling its Regeneron position. These manager opinions may influence sentiment but do not change the company’s fundamentals. Harbor Funds commentary American Century fund sale
• Negative Sentiment: Several firms reiterated that investors who purchased REGN between August 1, 2025 and May 15, 2026 may seek lead-plaintiff status by September 14, 2026. The allegations focus on whether Regeneron adequately disclosed the protocol and risks of the Phase 3 fianlimab-Libtayo melanoma study, which ultimately failed; notices cite an earlier decline of roughly $102 per share from the class-period high. The repeated announcements increase litigation visibility and could keep a risk discount on the shares. Hagens Berman class-action notice Robbins Geller deadline notice
• Negative Sentiment: Analyst commentary also highlighted reasons to avoid REGN, including recent underperformance versus the broader market, adding to the cautious tone around the shares. Reasons to avoid REGN

Regeneron Pharmaceuticals Stock Down 0.3%

REGN stock opened at $807.65 on Thursday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average price is $749.60 and its 200 day moving average price is $720.06. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $859.34. The company has a market cap of $83.16 billion, a P/E ratio of 19.96, a P/E/G ratio of 1.59 and a beta of 0.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same period last year, the company posted $12.81 earnings per share. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. On average, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were paid a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses technologies involving genetics, antibodies and other biologic treatments to advance therapies in areas such as eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease and rare disorders.

Regeneron’s marketed medicines include EYLEA and EYLEA HD for retinal diseases, Libtayo for certain cancers, Praluent for cardiovascular disease, Evkeeza for homozygous familial hypercholesterolemia and Veopoz for a rare immune disorder.